Scientists Find the Hidden Cell Type Letting Colorectal Tumors Dodge the Immune System

About 85% of colorectal cancers are classified as microsatellite stable, and for patients with this form of the disease, immunotherapy has been almost entirely useless. Checkpoint inhibitors that have transformed outcomes in other cancers produce little response here, leaving most patients reliant on chemotherapy and radiation. New research published in Cell Reports Medicine points to a specific population of cancer cells as a central culprit, and preliminary experiments suggest that neutralizing them could allow the immune system to finally gain a foothold.

WNT-Inhibitory Cancer Cells Found Predominantly in Advanced MSS Tumors

The study, led by Arshad Ayyaz's group at the University of Calgary, identified what they call WNT/beta-catenin inhibitory cancer cells, or WICCs. These cells are enriched in advanced-stage microsatellite stable colorectal cancers and express an unusual transcriptional program: rather than amplifying the WNT signaling that drives most colorectal tumor growth, they actively suppress it. Their defining markers include three WNT antagonists, NOTUM, NKD1, and APCDD1, that are nearly undetectable in normal colon tissue or in inflammatory bowel disease patients' epithelial cells. WICCs also sit at an unusual cellular crossroads, maintaining epithelial stem-cell features while showing partial characteristics of a mesenchymal transition, a hybrid state the researchers describe as a partial-EMT/epithelial-stem program. Tumors with high WICC enrichment were significantly more likely to carry mutations in APC, TP53, and KRAS, and the team confirmed that APC, p53, and KRAS mutations together were sufficient to induce the WICC program in mouse organoids.

WICC-Enriched Tumors Show Near-Total Immune Exclusion

Patients whose tumors are enriched for WICCs face a compounded problem. Analysis of the TCGA colorectal adenocarcinoma dataset revealed that WICC-high tumors are significantly depleted of CD8+ T cells, CD4+ T cells, natural killer cells, dendritic cells, and macrophages, the core cellular machinery of anti-tumor immunity. At the same time, these tumors show expansion of fibroblasts, endothelial cells, and mesenchymal lineages, hallmarks of a desmoplastic, angiogenic microenvironment that physically walls off immune cells. WICC enrichment also correlated with larger tumor size, more advanced pathological staging, and greater lymph node involvement. Patients with WICC-high tumors showed significantly poorer overall survival even after standard chemoradiation. The scale of immune exclusion is notable: across all colorectal cancer cell phenotypes the researchers catalogued, WICCs showed the lowest association with immune cell infiltration. For context, translational research converting laboratory findings into clinical tools has long identified immune exclusion as one of the central barriers to improving solid tumor outcomes, and the WICC program appears to be one of the mechanisms enforcing it.

How NOTUM Disarms CD8+ T Cells

The key effector appears to be NOTUM, a secreted enzyme the researchers describe as the primary mechanism by which WICCs suppress anti-tumor immunity. Single-molecule fluorescence in situ hybridization confirmed that high NOTUM expression and low CD8A expression co-occur in MSS tumors, while MSI-H tumors show the inverse pattern. When the team examined CD8+ T cells from WICC-high versus WICC-low primary tumors, and then treated T cells with recombinant NOTUM directly, a consistent picture emerged: NOTUM suppresses WNT-responsive genes in CD8+ T cells, including TCF7, CCR7, and BCL2. TCF7 supports T cell stemness; CCR7 governs migration into tumors; BCL2 promotes survival. Stripping all three simultaneously degrades T cell fitness, motility, and persistence. In effect, WICCs create a localized WNT-suppressed zone that compromises immune cells even as it is driven by a tumor whose growth depends on WNT activation elsewhere. The use of CRISPR-Cas9 and advanced organoid co-culture systems allowed the team to test this mechanistic model directly in engineered murine tumoroids.

Ablating WICCs or Deleting NOTUM Rescues T Cell Killing

The most striking results came from functional experiments. The team engineered murine tumoroids so that WICC cells, tagged at the Apcdd1 locus, could be selectively eliminated using a chemical switch (AP20187). When WICCs were ablated and the tumoroids were then co-cultured with CD8+ T cells, 72% of tumoroids exceeded 50% apoptosis, meaning the immune cells were finally killing the cancer. Re-introducing recombinant NOTUM into those same cultures partially rescued tumoroid survival, confirming NOTUM as a key functional mediator rather than just a correlate. The in vivo experiments were equally clear: Notum-knockout tumors in immunocompetent mice grew more slowly and attracted robust CD8+ T cell infiltration. When OT-1 CD8+ T cells were transferred adoptively into mice carrying established Notum-knockout tumors, the tumors were completely eliminated. The same adoptive transfer into NOTUM-expressing tumors produced no such clearance. These findings build on the growing toolkit of advanced experimental designs that allow researchers to isolate causal relationships in complex tumor-immune systems.

Open Questions About WICCs and the Broader Tumor Microenvironment

The study is explicit about what remains unknown. The precise effects of WICC-derived factors on dendritic cells, macrophages, regulatory T cells, and cancer-associated fibroblasts have not yet been characterized. How WICC ablation would reshape the spatial architecture of the tumor microenvironment, the cytokine networks, and antigen presentation pathways is also unresolved. The patient survival analysis was limited by cohort size: when tumors were stratified by both WICC enrichment and a second stem-cell population score, the sample was too small to reach statistical significance for overall survival differences. And while the mouse models are informative, the jump to human therapeutic targeting of NOTUM or WICCs directly will require its own clinical development path.

A Targetable Vulnerability in Tumors That Have Resisted Everything Else

The research frames WICCs and NOTUM as a cancer-specific vulnerability, one that is nearly absent in normal colonic epithelium, making them an attractive therapeutic target that might spare healthy LGR5+ stem cells. Inhibiting NOTUM enzymatic activity, or depleting WICC populations through other means, could theoretically convert an immune-excluded MSS colorectal tumor into one that CD8+ T cells can enter and destroy. That would represent a meaningful change in the treatment landscape for a cancer subtype that currently has few good options once it reaches advanced stages. The results are preliminary and the path to clinical application is long, but for the roughly 85% of colorectal cancer patients whose tumors are MSS, a mechanistic explanation for immune failure, and a plausible target to reverse it, is a significant step forward.

Evidence rating

INVESTIGATIONAL — 76/100

Caveats:

• Funding source is not disclosed, so independent verification of this work has not yet been confirmed.
• Much of the mechanistic evidence relies on engineered mouse tumoroids and adoptive cell transfer models; direct human clinical validation is not yet available.
• Patient cohort sizes were limited, preventing statistically significant survival comparisons in key subgroup analyses.
• Effects of WICCs on other immune cell types (dendritic cells, macrophages, Tregs) remain undefined.

Integrative single-cell transcriptomic study combining human CRC tissue analysis, patient-derived tumoroids, and immunocompetent mouse models. Demonstrates a mechanistic causal chain from WICC-derived NOTUM secretion to CD8+ T cell dysfunction, but relies heavily on engineered murine systems rather than large-scale human clinical cohorts. Not yet independently replicated, and funding source is undisclosed.

References

1. Julian Chua, Arshdeep Kaur, Fynnis Mitchell, et al. (2026). A tumor-intrinsic WNT-inhibitory NOTUM program drives immune resistance in microsatellite stable colorectal cancer. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2026.102776
2. Translational medical research: present and future. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776310/
3. Gehendra Mahara, Cuihong Tian, Xiaojia Xu, Wei Wang (2023). Revolutionising health care: Exploring the latest advances in medical sciences. Journal of Global Health. https://doi.org/10.7189/jogh.13.03042
4. Jonathan P Meizoso, James Byrne, Vanessa P Ho, Matthew D Neal, Deborah M Stein, Elliott R Haut (2024). Advanced and alternative research methods for the acute care surgeon scientist. Trauma Surgery & Acute Care Open. https://doi.org/10.1136/tsaco-2023-001320